Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial

When Pfiz­er laid out the am­bi­tious vi­sion for its new on­col­o­gy di­vi­sion in Feb­ru­ary, it an­nounced that it was tak­ing the an­ti­body-drug con­ju­gate sigvotatug ve­dotin di­rect­ly from Phase 1 to Phase 3. Now the drug­mak­er is re­leas­ing the up­dat­ed da­ta that con­vinced it to ac­cel­er­ate the drug ac­quired from its $43 bil­lion deal for Seagen last year.

In up­dat­ed re­sults re­leased Thurs­day, Pfiz­er said that about one-fifth of lung can­cer pa­tients who re­ceived sigvotatug ve­dotin saw their tu­mors shrink by at least 30%. And in 40 pa­tients with non-squa­mous, non-small cell lung can­cer, which in­cludes forms of lung can­cer that typ­i­cal­ly start from the pe­riph­ery of the lungs, 13 pa­tients saw their tu­mors shrink by at least that amount, a 32.5% re­sponse rate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.